CN111239227B - Erythrocyte volume correction method and biosensor testing device - Google Patents
Erythrocyte volume correction method and biosensor testing device Download PDFInfo
- Publication number
- CN111239227B CN111239227B CN202010110722.8A CN202010110722A CN111239227B CN 111239227 B CN111239227 B CN 111239227B CN 202010110722 A CN202010110722 A CN 202010110722A CN 111239227 B CN111239227 B CN 111239227B
- Authority
- CN
- China
- Prior art keywords
- hematocrit
- blood
- blood sample
- hct
- ranges
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012937 correction Methods 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 39
- 238000012360 testing method Methods 0.000 title claims abstract description 37
- 210000003743 erythrocyte Anatomy 0.000 title claims description 25
- 210000004369 blood Anatomy 0.000 claims abstract description 135
- 239000008280 blood Substances 0.000 claims abstract description 135
- 238000005534 hematocrit Methods 0.000 claims abstract description 133
- 239000012491 analyte Substances 0.000 claims abstract description 49
- 150000003278 haem Chemical class 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims 3
- 238000005259 measurement Methods 0.000 abstract description 10
- 238000001514 detection method Methods 0.000 abstract description 7
- 238000013461 design Methods 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 36
- 239000008103 glucose Substances 0.000 description 36
- 239000003153 chemical reaction reagent Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- -1 potassium ferricyanide Chemical compound 0.000 description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 6
- VOZDNCFKGOLECZ-BTVCFUMJSA-N 2-hydroxypropanoic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VOZDNCFKGOLECZ-BTVCFUMJSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000003219 hemolytic agent Substances 0.000 description 4
- KYMNSBSWJPFUJH-UHFFFAOYSA-N iron;5-methylcyclopenta-1,3-diene;methylcyclopentane Chemical compound [Fe].C[C-]1C=CC=C1.C[C-]1[CH-][CH-][CH-][CH-]1 KYMNSBSWJPFUJH-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- FHCPAXDKURNIOZ-UHFFFAOYSA-N tetrathiafulvalene Chemical compound S1C=CSC1=C1SC=CS1 FHCPAXDKURNIOZ-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- GBDZMMXUOBAJMN-UHFFFAOYSA-K azane;ruthenium(3+);trichloride Chemical compound N.N.N.N.N.N.[Cl-].[Cl-].[Cl-].[Ru+3] GBDZMMXUOBAJMN-UHFFFAOYSA-K 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003891 environmental analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/4163—Systems checking the operation of, or calibrating, the measuring apparatus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/27—Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a method for correcting hematocrit, which comprises the following steps: s1, detecting blood sample parameters of a blood sample; s2, measuring hematocrit: detecting hematocrit (HCT%) in the blood sample based on a correlation curve of a blood sample parameter to hematocrit; s3, measuring initial analyte concentration value C First stage (ii) a S4, analyte concentration correction: using the measured hematocrit of blood (HCT%) and the measured initial analyte concentration value C Beginning of the design Calculating the final corrected analyte concentration value C Final (a Chinese character of 'gan') . The biosensor testing device with the hematocrit correction is further disclosed, and a correlation curve of the hematocrit (HCT%) and the blood sample parameter in the hematocrit correction method is programmed and input into the biosensor testing device. The invention can effectively eliminate the influence of the hematocrit on the analyte concentration measurement and improve the detection accuracy.
Description
Technical Field
The invention belongs to the field of biosensing, and relates to a hematocrit correction method and a biosensor testing device applying the hematocrit correction method.
Background
Biosensors are widely used in the fields of medical detection, environmental analysis, food detection, etc., and electrochemical biosensors are a technology for performing qualitative or quantitative analysis on an analyte by chemically reacting with the analyte in a certain manner and converting reaction signals into electrical signals that can be analyzed and measured. The sensor has the characteristics of simple operation, small sample amount, high accuracy, low manufacturing cost, capability of being used for real-time detection and the like, but the conventional electrochemical biosensor is easily influenced by the hematocrit of blood when testing the concentration of an analyte in a blood sample, so that the concentration result of the analyte is interfered. Most of the existing hematocrit test methods use a blood flow rate method, a conductance method or an impedance method to correct the analyte concentration. The methods are greatly influenced by the stability of a printing electrode of the sensor and the properties of a hydrophilic layer film material, so that the development of a new detection method for improving the sensitivity and the accuracy of a detection means is a main problem to be solved urgently.
Disclosure of Invention
In view of the above technical problems, the present invention provides a hematocrit correction method and a biosensor testing device using the same, which can eliminate the influence of hematocrit on analyte concentration measurement and improve the accuracy of detection.
In order to achieve the purpose, the invention adopts the technical scheme that:
a hematocrit correction method includes the following steps:
s1, detecting blood sample parameters of a blood sample;
s2, measuring hematocrit: detecting hematocrit (HCT%) in the blood sample based on a correlation curve of a blood sample parameter to hematocrit;
s3, measuring initial analyte concentration value C First stage ；
S4, analyte concentration correction: using the measured hematocrit of blood (HCT%) and the measured initial analyte concentration value C Beginning of the design Calculating the final corrected analyte concentration value C of the analyte Final (a Chinese character of 'gan') 。
In a preferred embodiment, the measured response current (I) of the blood sample is used to correct the measured analyte content by converting the current hematocrit (HCT%) in the blood using a correlation curve between the hematocrit (HCT%) and the response current (I) of the blood sample.
Further, the method for determining the correlation curve of the blood sample response current (I) and the hematocrit comprises the following steps:
s2.1, obtaining standard hematocrit of different hematocrit blood samples;
s2.2, converting the blood sample with the standard hematocrit value into blood samples with different heme concentrations;
s2.3, obtaining response currents (I) of blood samples with different heme concentrations;
s2.4, establishing a correlation curve of the heme concentration and the response current (I) of the blood sample;
s2.5, converting the correlation curve of the hemoglobin concentration and the response current (I) of the blood sample into the correlation curve of the hematocrit and the response current (I) of the blood sample.
Preferably, the correlation equation of the hematocrit (HCT%) with the blood current (I) is HCT% = a X (I) + b; wherein a ranges from 0 to +0.2 and b ranges from 0 to +0.2.
More preferably, the correlation equation of the hematocrit (HCT%) with the blood current (I) is HCT% = c In (I) + d; wherein c ranges from 0 to +1,d ranges from 0 to +1.
In a preferred embodiment, the measured analyte content is corrected by using the measured red blood cell impedance phase angle (tan φ) in the blood sample and using a correlation curve between hematocrit (HCT%) and red blood cell impedance phase angle to convert to obtain the current hematocrit (HCT%) in the blood.
Further, the method for determining the correlation curve of the impedance phase angle (tan phi) of the red blood cells and the hematocrit (HCT%) comprises the following steps:
s200, testing impedance phase angles (tan phi) of red blood cells in standard different hematocrit blood samples;
s210, establishing correlation curves of different hematocrit values and impedance phase angles (tan phi) of the red blood cells.
Preferably, the correlation equation of the volume of packed red blood cells (HCT%) and the impedance phase angle of red blood cells (tan phi) is HCT% = e + tan phi 2+ f + tan phi + g; wherein e ranges from-0.01 to 0,f ranges from-0.01 to +0.01 and g ranges from 0 to 0.1.
Preferably, the analyte final corrected analyte concentration value C is calculated Final (a Chinese character of 'gan') The equation of (c) is:
C final (a Chinese character of 'gan') ＝C First stage (k 3+ k1 HCT%)/(1 + k2 HCT%); wherein k1 ranges from-1 to +1, k2 ranges from-1 to +1, and k3 ranges from-2 to +2.
More preferably, an analyte final corrected analyte concentration value C is calculated Final (a Chinese character of 'gan') The equation of (a) is:
C final (a Chinese character of 'gan') ＝k5*C First stage /(1 + k4 + HCT%) where k4 ranges from-1 to +1,k5 ranges from 0 to +2.
The invention also discloses a biosensor testing device with hematocrit correction, and the correlation curve of the hematocrit (HCT%) and the blood sample parameters in the hematocrit correction method is programmed and input into the biosensor testing device.
The invention has the following beneficial effects:
the invention relates to a hematocrit correction method and an electrochemical biosensor test device with hematocrit correction. The electrochemical biosensor determines the hematocrit of blood by the corresponding current value of the hemoglobin concentration of blood or by the phase angle tan phi of the impedance of the red blood cells of blood. And then correcting through the determined analyte concentration correction equation to calculate the final corrected concentration value of the analyte. The method is simple and easy to implement, has few interference factors and accurate test, can effectively eliminate the influence of the hematocrit on the determination of the concentration of the analyte, and improves the accuracy and the sensitivity of the result.
Drawings
FIG. 1 is a schematic structural diagram of a biosensor with hematocrit correction according to an embodiment of the present invention.
FIG. 2 is a schematic flow chart of a method for measuring hematocrit in a biosensor according to an embodiment of the present invention.
FIG. 3 is a graph showing the conversion between hematocrit and hemoglobin in the biosensor according to the embodiment of the present invention.
FIG. 4 is a graph showing the linear correlation between the hematocrit calculated in example 1 of the present invention and the hematocrit measured as a standard.
FIG. 5 is a graph comparing results before and after correction of the analyte concentration by hematocrit in example 2-1 of the present invention.
FIG. 6 is a graph comparing the results before and after correction of the analyte concentration by hematocrit in example 2-2 of the present invention.
FIG. 7 is a graph comparing results before and after correction of analyte concentration by hematocrit in examples 2-3 of the present invention.
FIG. 8 is a schematic structural diagram of a biosensor with hematocrit correction according to another embodiment of the present invention.
FIG. 9 is a graph showing the correlation between different hematocrit values and the impedance phase angle tan φ of red blood cells in example 3 of the present invention;
FIG. 10 is a graph showing the linear correlation between the hematocrit calculated in example 3 of the present invention and the hematocrit of the measured standard;
FIG. 11 is a graph showing a comparison of the results before and after correction of the blood glucose concentration by hematocrit in example 4 of the present invention.
Wherein, 1, an electrode output end; 2. an electrode output end; 3. an electrode output end; 4. an electrode output end; 5. an electrode output end; 6. a reaction electrode; 7. a reaction electrode; 8. a counter electrode; 9. a first channel (first reagent layer); 10. a second channel (second reagent layer); 11. an insulating layer; 12. a hydrophilic layer; 13. a base layer; 14. a liquid inlet to be detected; 15. air holes; 16 conductive traces. 31. An electrode output end; 32. an electrode output end; 33. an electrode output end; 34. an electrode output end; 35. an electrode output end; 36 conductive lines; 37. a reaction electrode; 38. a first auxiliary electrode; 39. a working electrode; 310. a second auxiliary electrode; 311. an insulating layer; 312. a base layer; 313. a reagent layer; 314. a hydrophilic film layer 315, a liquid inlet to be detected; 316. air hole
Detailed Description
In order to make it possible for those skilled in the relevant art to understand the technical solutions of the present invention, the technical solutions in the embodiments of the present invention are completely and clearly described in conjunction with the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only some embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The equation of the curve of hematocrit (HCT%) versus blood sample parameters is programmed into the test instrument used with the electrochemical biosensor. FIG. 1 is a schematic diagram of a two-channel electrochemical biosensor with hematocrit correction according to this embodiment, which includes a substrate layer 13, a conductive layer disposed on the substrate layer 13, and an insulating layer 11 disposed on the conductive layer. The upper end of the conducting layer comprises electrode output ends 1-5, the lower end of the conducting layer comprises a first working electrode 6, a second working electrode 7 and a counter electrode 8 shared by the first working electrode 6 and the second working electrode 7. Conductive circuits 16 are connected between the first working electrode 6, the second working electrode 7, the counter electrode 8 and the electrode output terminals 1 to 5. The first working electrode 6 and the counter electrode 8 constitute a first electrode group, and the second working electrode 7 and the counter electrode 8 constitute a second electrode group. The insulating layer 11 covers the portion above the pins of the detection electrode group, and two inverted-Y-shaped reaction channels, namely a first channel 9 (first reagent layer) and a second channel 10 (second reagent layer), are arranged according to the arrangement of the electrodes of the conductive layer. A hydrophilic layer 12 is provided in the reaction channel. The front end of the hydrophilic layer 12 is provided with a liquid inlet 14 to be detected; the hydrophilic layers 12 at the rear ends of the reaction channels are respectively provided with air holes 15. The method for measuring the hemoglobin concentration by using the electrochemical biosensor of the embodiment comprises the following test conditions: respectively applying the reaction solution to a first reaction channel and a second reaction channel under the constant potential condition of 0.2-1V for reaction; the buffer solution in the first reagent layer 9 is used to maintain the pH value in the range of 6 to 8, and the buffer solution in the second reagent layer 10 is used to maintain the pH value in the range of 5 to 8. The first reagent layer 9 includes a hemolytic agent, a first electron mediator, a first stabilizer; the second reagent layer 10 includes a surfactant, a second electron mediator, an enzyme, and a second stabilizer.
The first electron mediator comprises one of potassium ferricyanide, ferrocene, dimethylferrocene and ferrocene diformate. The second electron mediator comprises one of potassium ferricyanide, hexaammonium ruthenium trichloride, tetrathiafulvalene, ferrocene, dimethylferrocene and ferrocene diformate. The hemolytic agent in the first reagent layer comprises one or more of saponin, dodecyl sulfuric acid, hexadecyl trimethyl ammonium bromide and triton. The surfactant in the second reagent layer comprises one or more of saponin, dodecyl sulfuric acid, cetyl trimethyl ammonium bromide and triton.
FIG. 2 is a schematic flow chart of the hematocrit measurement method in the electrochemical biosensor of this embodiment.
The method comprises the following steps:
s2.1, obtaining standard hematocrit values of different hematocrit blood samples by using a capillary method or a blood cell technology instrument method;
s2.2, converting the blood sample with the standard hematocrit value into blood samples with different heme concentrations;
s2.3, obtaining response currents (I) of blood samples with different heme concentrations;
s2.4, establishing a correlation curve of the heme concentration and the response current (I) of the blood sample;
and S2.5, converting the correlation curve of the heme concentration and the response current (I) of the blood sample into the correlation curve of the hematocrit and the response current (I) of the blood sample.
The correlation equation of hematocrit (HCT%) to blood sample response current (I) may be HCT% = a × In (I) + b; wherein a ranges from about 0 to about +1,b ranges from about 0 to about +1. The equation for the plot of hematocrit (HCT%) versus heme test current value (I) is programmed into a test instrument used with an electrochemical biosensor.
S2.6, determining the hematocrit value (HCT%) of the detected blood sample according to the correlation curve of the determined current and the hematocrit.
Using the measured hematocrit value (HCT%) and the measured analyte concentration value C Beginning of the design Calculating final concentration value C of analyte Final (a Chinese character of 'gan') 。
Calculating the final concentration value C of the analyte Final (a Chinese character of 'gan') The equation of (c) may be: c Final (a Chinese character of 'gan') ＝k2*C Beginning of the design /(1 + k1 + HCT%), where k1 ranges from about-1 to about +1 and k2 ranges from about 0 to about +2.
The following is a specific description of the implementation of the present invention using the example of testing blood glucose in a blood sample.
Example 1: and (4) determining the hematocrit measurement equation.
The test items are mainly glucose concentration in whole blood or venous blood, and the calibration test items are mainly analytes in whole blood, such as glucose, total cholesterol, creatinine, blood ketone, urea nitrogen and the like. The first electrode group and the second electrode group adopt: gold electrodes, carbon electrodes, silver electrodes or any combination thereof.
The test conditions are that the reaction is carried out under the constant potential condition of 0.2 to 1 volt respectively applied to the first electrode group and the second electrode group. The buffer solution in the first reagent layer is used to maintain the pH in the range of 6 to 8, and the buffer solution in the second reagent layer is used to maintain the pH in the range of 5 to 8. The measuring method comprises a capillary method and a blood cell counter method.
The first reagent layer comprises hemolytic agent, electron mediator, stabilizer and the like; the second reagent layer includes a surfactant, an electron mediator, an enzyme, a stabilizer, and the like. The electron mediator in the first reagent layer comprises one of potassium ferricyanide, ferrocene, dimethylferrocene, ferrocene diformate and the like, and the electron mediator in the second reagent layer comprises one of potassium ferricyanide, ruthenium, tetrathiafulvalene, ferrocene, dimethylferrocene, ferrocene diformate and the like. The hemolytic agent in the first reagent layer comprises one or any combination of saponin, dodecyl sulfuric acid, hexadecyl trimethyl ammonium bromide, triton and the like; the surfactant in the second reagent layer comprises one or any combination of saponin, dodecyl sulfuric acid, hexadecyl trimethyl ammonium bromide, triton and the like.
A1. Preparing a plurality of blood samples with the same blood glucose concentration, wherein the blood glucose concentration is 300mg/dL, and adjusting the hematocrit to 10%, 20%, 30%, 40%, 50%, 60% and 70% respectively.
A2. The standard hematocrit blood samples were converted to blood samples of different hemoglobin concentrations as shown in fig. 3. And blood glucose sensors were used to measure the values of the blood sample response currents at different hemoglobin concentrations. As shown in table 1:
| HCT％ | hemoglobin concentration (g/L) | Current (uA) |
| 10％ | 33.3 | 1.04 |
| 20％ | 66.7 | 1.48 |
| 30％ | 100 | 2.00 |
| 40％ | 133.2 | 2.92 |
| 50％ | 167 | 3.66 |
| 60％ | 199 | 5.30 |
| 70％ | 233 | 7.01 |
TABLE 1
A3. Using the data in table 1, linear fitting is performed with the current value as the X-axis and the hematocrit as the Y-axis to obtain the equation of the relationship between the blood (HCT%) and the current value (I), i.e.
HCT％＝0.315ln(x)+0.0828 (F-1)
The measured current value (I) was substituted into the above-mentioned F-1 equation to obtain a calculated hematocrit of blood, and the correlation with the hematocrit of the actually measured standard is shown in FIG. 4.
As shown in FIG. 4, the slope of the correlation curve is 0.9564, the intercept is 0.0235, and the linear correlation coefficient R2 is 0.9978, which shows that the correlation is better.
The correlation equation (F-1) of hematocrit (HCT%) and current (I) in A3 was programmed into the instrument internal calibration chip used with the electrochemical biosensor.
Example 2: final blood sample blood glucose concentration calibration function equation determination
B1-1: preparing multiple blood samples, adjusting hematocrit to 10%, 20%, 30%, 40%, 50%, 60%, 70%, and blood glucose concentration to 110mg/dL, and calibrating with YSI 2300STAT PLUS glucose lactate analyzer, namely C YSI =110mg/dL. Testing of blood glucose concentration C with a blood glucose electrochemical sensor without hematocrit correction equation First stage . As shown in table 2.
TABLE 2
B1-2: preparing multiple blood samples, adjusting hematocrit to 10%, 20%, 30%, 40%, 50%, 60%, 70%, and blood glucose concentration to 300mg/dL, and calibrating with YSI 2300STAT PLUS glucose lactate analyzer, namely C YSI =300mg/dL. Testing of blood glucose concentration C with a blood glucose electrochemical sensor without hematocrit correction equation First stage . As shown in table 3.
| HCT％ | C First stage (mg/dL) |
| 10％ | 440 |
| 20％ | 402 |
| 30％ | 347 |
| 40％ | 294 |
| 50％ | 252 |
| 60％ | 196 |
| 70％ | 172 |
TABLE 3
B1-3: preparing multiple blood samples, adjusting hematocrit to 10%, 20%, 30%, 40%, 50%, 60%, 70%, and blood glucose concentration to 500mg/dL, and calibrating with YSI 2300STAT PLUS glucose lactate analyzer, namely C YSI =500mg/dL. Testing of blood glucose concentration C with a blood glucose electrochemical sensor without hematocrit correction equation First stage . As shown in table 4.
| HCT％ | C First stage (mg/dL) |
| 10％ | 699 |
| 20％ | 670 |
| 30％ | 570 |
| 40％ | 498 |
| 50％ | 423 |
| 60％ | 337 |
| 70％ | 261 |
TABLE 4
Statistical analysis was performed using the initial data in tables 2, 3, and 4 to obtain a calibration function for the final analyte concentration as:
C final (a Chinese character of 'gan') ＝0.61*C First stage /(1-0.97*HCT％) (F-2)
The blood glucose concentration correction equation (F-2) obtained in example 2 was programmed and input into the internal chip of the instrument used with the electrochemical biosensor.
Fig. 5, fig. 6, and fig. 7 are comparison graphs of three different blood glucose concentrations before and after hematocrit correction, as shown in fig. 5, fig. 6, and fig. 7, the measured blood glucose concentration before hematocrit correction has a larger deviation from the YSI measurement value, and the blood glucose concentration after hematocrit correction has better consistency with the YSI test result.
The electrochemical biosensor using the hematocrit measurement and correction method of the invention is not affected by hematocrit when testing the concentration of blood analytes, and the test result is more accurate and reliable.
The following examples correct the determined analyte content by using the measured red blood cell impedance phase angle (tan. Phi.) in a blood sample, and using a correlation curve of hematocrit (HCT%) and red blood cell impedance phase angle to convert to the current hematocrit (HCT%) in the blood.
Fig. 8 is a schematic structural diagram of the electrochemical biosensor for measuring blood impedance phase angle according to the present embodiment, which includes a substrate layer 312, a conductive layer on the substrate layer 312, and an insulating layer 311 disposed on the conductive layer. One end of the conducting layer comprises 5 electrode output ends 31-35, the other end of the conducting layer is sequentially provided with a first auxiliary electrode 39, a working electrode 38, a reaction electrode 37 and a second auxiliary electrode 310, a conducting circuit 36 is connected between the reaction electrode 37, the first auxiliary electrode 39, the working electrode 38, the second auxiliary electrode 310 and the electrode output ends 31-35, a hydrophilic film layer 314 is arranged on a reaction channel at the lower end of the basal layer, and the lower end of the hydrophilic film layer 314 is provided with a liquid inlet 315 to be detected; the upper end of the hydrophilic thin film layer 314 is provided with an air hole 316, and the reaction electrode 37 and the second auxiliary electrode 310 are provided with a reagent layer 313.
The buffer solution in the reagent layer 313 maintains the pH in the range of 6 to 8.
The reagent layer 313 includes a surfactant, an electron mediator, an enzyme, and a stabilizer. The electron mediator comprises one of potassium ferricyanide, ruthenium, tetrathiafulvalene and ferrocene. The surfactant comprises one or more of saponin, dodecyl sulfuric acid, cetyl trimethyl ammonium bromide and triton. The reaction electrode and the auxiliary electrode are silver electrodes.
The method for measuring the blood impedance phase angle by the electrochemical biosensor of the embodiment comprises the following measurement conditions: the reaction is carried out under the condition of constant potential between 0.2V and 1.0V between the reaction electrode 7 and the second auxiliary electrode 10; the amplitude of the AC impedance of the AC voltage signal applied to the reaction electrode 7 and the second auxiliary electrode 10 is 0.1-0.4V, and the frequency is 100-20000Hz.
The method for determining the correlation curve of the impedance phase angle (tan phi) of the red blood cells and the hematocrit (HCT%) of the red blood cells comprises the following steps:
S200，by capillary or cytometryTesting the red blood cell impedance phase angle (tan phi) in standard different hematocrit blood samples;
s210, establishing correlation curves of different hematocrit values and impedance phase angles (tan phi) of the red blood cells;
s220, determining the hematocrit value (HCT%) of the blood sample according to the correlation curve of the predetermined impedance phase angle and the hematocrit.
The correlation equation of the volume of packed red blood cells (HCT%) and the impedance phase angle of red blood cells (tan phi) is HCT% = e tan phi 2+ f tan phi + g; wherein e ranges from-0.01 to 0,f ranges from-0.01 to +0.01 and g ranges from 0 to 0.1.
Example 3: and (4) determining the hematocrit measurement equation.
The test items are mainly glucose concentration in whole blood or venous blood, and the calibration test items are mainly analytes in whole blood, such as glucose, total cholesterol, creatinine, blood ketone, uric acid and the like. The first electrode group and the second electrode group adopt: gold electrodes, carbon electrodes, silver electrodes, or any combination thereof.
The test conditions were that the reaction was carried out under a constant potential applied to the second electrode group of 0.2-1.0V. The amplitude of the AC impedance of the AC voltage signal applied to the first electrode set is 0.1-0.4V, and the frequency is 100-20000Hz. The buffer solution in the second reagent layer is used to maintain the pH in the range of 6 to 8. The measurement methods include capillary method, cytometry method and the like. The second reagent layer comprises a surfactant, an electron mediator, an enzyme, a stabilizer and the like; wherein the electron mediator comprises one of potassium ferricyanide, hexaammonium ruthenium trichloride, tetrathiafulvalene, ferrocene and the like; the surfactant comprises one or any combination of saponin, dodecyl sulfuric acid, cetyl trimethyl ammonium bromide, triton, etc.
A1. Preparing a plurality of blood samples with the same blood glucose concentration, wherein the blood glucose concentration is 110mg/dL, and adjusting the hematocrit to 10%, 20%, 30%, 40%, 50%, 60% and 70% respectively.
A2. Different hematocrit values (HCT%) of the blood samples were tested for impedance phase angle values phi with the blood glucose sensor. As shown in table 5:
| HCT％ | impedance phase angle value phi (DEG) | tanφ |
| 10％ | 74.5 | 3.16 |
| 20％ | 72.6 | 3.19 |
| 30％ | 71.4 | 2.98 |
| 42％ | 68.7 | 2.56 |
| 50％ | 63.4 | 2.00 |
| 60％ | 56.7 | 1.52 |
| 70％ | 45.9 | 1.03 |
TABLE 5
A3. Using the data in table 5, with the erythrocyte impedance phase angle tangent tan phi as the X axis and the hematocrit of blood as the Y axis, a linear fit is performed, as shown in fig. 9, to obtain the equation of the relationship between blood (HCT%) and impedance phase angle tan phi, that is:
HCT％＝-0.0334*tanφ^2-0.0724*tanφ+0.8019 (F-3)
the measured impedance phase angle tan phi was substituted into the above-described F-3 equation to obtain a calculated hematocrit, and the correlation with the measured standard hematocrit is shown in FIG. 10.
As shown in FIG. 10, the slope of the correlation curve is 0.9924, the intercept is 0.0028, and the linear correlation coefficient R2 is 0.9916, which shows that the correlation is better.
The correlation equation (F-1) of hematocrit (HCT%) and impedance phase angle tan φ in A3 was programmed into the instrument internal calibration chip used with the electrochemical biosensor.
Example 4: and finally determining the blood glucose concentration in the blood sample by using a calibration function equation.
B1-1: preparing multiple blood samples, adjusting hematocrit to 10%, 20%, 30%, 40%, 50%, 60%, 70%, and blood glucose concentration to 110mg/dL, and calibrating with YSI 2300STAT PLUS glucose lactate analyzer, namely C YSI =110mg/dL. Testing of blood glucose concentration C with a blood glucose electrochemical sensor without hematocrit correction equation First stage . As shown in table 6:
| HCT％ | C first stage (mg/dL) |
| 10％ | 159 |
| 20％ | 143 |
| 30％ | 133 |
| 40％ | 111 |
| 50％ | 95 |
| 60％ | 75 |
| 70％ | 60 |
TABLE 6
Statistical analysis was performed using the initial data in table 6 to obtain a calibration function for the final analyte concentration as:
C terminal ＝0.59*C First stage /(1-0.99*HCT％) (F-4)
The blood glucose concentration correction equation (F-4) obtained in example 4 was programmed and input into the internal chip of the instrument used with the electrochemical biosensor.
Fig. 11 is a comparison graph of blood glucose concentration before and after hematocrit correction, and as shown in fig. 11, the measured blood glucose concentration before hematocrit correction has a large deviation from the YSI measurement value, and the blood glucose concentration after hematocrit correction has a good consistency with the YSI measurement result.
The electrochemical blood glucose test strip using the hematocrit measurement and correction method of the invention is not affected by hematocrit when testing blood glucose concentration, and the test result is more accurate and reliable.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all changes in equivalent structures or equivalent processes, which are made by using the contents of the specification and the drawings, or directly or indirectly applied to other related technical fields, are also included in the scope of the present invention.
Claims (6)
1. A hematocrit correction method, comprising the steps of:
s1, detecting blood sample parameters of a blood sample;
s2, measuring hematocrit: detecting the hematocrit in the blood sample according to the correlation curve of the blood sample parameters and the hematocrit;
s3, measuring the initial analyte concentration value C First stage ；
S4, analyte concentration correction: using the measured blood red cell pressure and the measured initial analyte concentration value C First stage Calculating the final corrected analyte concentration value C of the analyte Final (a Chinese character of 'gan') ；
Converting the current hematocrit in the blood by using the measured response current of the blood sample and a correlation curve of the hematocrit and the response current of the blood sample, and correcting the content of the measured analyte; the method for determining the correlation curve of the response current of the blood sample and the hematocrit comprises the following steps:
s2.1, obtaining standard hematocrit of different hematocrit blood samples;
s2.2, converting the blood sample with the standard hematocrit value into blood samples with different heme concentrations;
s2.3, obtaining response currents of blood samples with different heme concentrations;
s2.4, establishing a correlation curve of the heme concentration and the response current of the blood sample;
s2.5, converting the correlation curve of the heme concentration and the response current of the blood sample into the correlation curve of the hematocrit and the response current of the blood sample;
the correlation equation of hematocrit to blood current is:
HCT% = a X (I) + b; where a ranges from 0 to +0.2, b ranges from 0 to +0.2, HCT% is hematocrit, and I is blood current.
2. The hematocrit correction method of claim 1, wherein the correlation equation of hematocrit and blood current is:
HCT% = c In (I) + d; wherein c ranges from 0 to +1,d ranges from 0 to +1.
3. A hematocrit correction method, comprising the steps of:
s1, detecting blood sample parameters of a blood sample;
s2, measuring hematocrit: detecting the hematocrit in the blood sample according to the correlation curve of the blood sample parameters and the hematocrit;
s3, measuring initial analyte concentration value C First stage ；
S4, analyte concentration correction: using the measured blood red cell pressure and the measured initial analyte concentration value C First stage Calculating the final corrected analyte concentration value C Terminal ；
Testing the impedance phase angle of the red blood cells in the standard blood samples with different hematocrit values, and establishing a correlation curve of the impedance phase angles of the red blood cells and the different hematocrit values; the measured impedance phase angle of the red blood cells in the blood sample is used for converting a correlation curve of the hematocrit and the impedance phase angle of the red blood cells to obtain the current hematocrit in the blood, and the content of the measured analyte is corrected;
the correlation equation of hematocrit to red blood cell impedance phase angle is:
HCT% = e + tan phi ^2+ f + tan phi + g; wherein e ranges from-0.01 to 0,f ranges from-0.01 to +0.01, g ranges from 0 to 0.1, HCT% is hematocrit, and tan φ is red cell impedance phase angle.
4. The hematocrit correction method according to any one of claims 1 to 3,
calculating the analyte Final corrected analyte concentration value C Final (a Chinese character of 'gan') The equation of (a) is:
C final (a Chinese character of 'gan') ＝C First stage (k 3+ k1 HCT%)/(1 + k2 HCT%); wherein k1 ranges from-1 to +1, k2 ranges from-1 to +1, and k3 ranges from-2 to +2.
5. The hematocrit correction method according to any one of claims 1 to 3,
calculating the analyte Final corrected analyte concentration value C Final (a Chinese character of 'gan') The equation of (a) is:
C final (a Chinese character of 'gan') ＝k5*C First stage /(1 + k4 + HCT%) where k4 ranges from-1 to +1 and k5 ranges from 0 to +2.
6. A biosensor test device for performing the method of claim 1, wherein: the biosensor test device is programmed with an input hematocrit to blood sample parameter correlation curve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010110722.8A CN111239227B (en) | 2020-02-24 | 2020-02-24 | Erythrocyte volume correction method and biosensor testing device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010110722.8A CN111239227B (en) | 2020-02-24 | 2020-02-24 | Erythrocyte volume correction method and biosensor testing device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111239227A CN111239227A (en) | 2020-06-05 |
| CN111239227B true CN111239227B (en) | 2023-03-03 |
Family
ID=70869325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010110722.8A Active CN111239227B (en) | 2020-02-24 | 2020-02-24 | Erythrocyte volume correction method and biosensor testing device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111239227B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111812175B (en) * | 2020-06-30 | 2022-06-14 | 江苏鱼跃医疗设备股份有限公司 | Blood detection method for reducing interference of hematocrit and biosensor |
| CN111982987B (en) * | 2020-08-27 | 2023-04-07 | 江苏鱼跃医疗设备股份有限公司 | Glucose sensor and measurement correction method |
| CN112485438B (en) * | 2020-11-10 | 2022-07-22 | 深圳市科曼医疗设备有限公司 | Specific protein reaction detection method and device |
| CN113063833B (en) * | 2021-03-12 | 2023-09-08 | 三诺生物传感股份有限公司 | Measurement method of hematocrit |
| CN114235906B (en) * | 2021-11-09 | 2024-01-05 | 江苏鱼跃凯立特生物科技有限公司 | Method for detecting blood glucose concentration in real time in-vitro blood glucose degradation process |
| CN114371195B (en) * | 2021-12-31 | 2023-06-30 | 无锡博慧斯生物医药科技有限公司 | Correction method for hematocrit |
| CN115901885B (en) * | 2023-02-15 | 2023-05-12 | 可孚医疗科技股份有限公司 | Metabolic index detection method, system and electrochemical measurement system |
| CN116577388B (en) * | 2023-07-13 | 2023-09-19 | 南京晶捷生物科技有限公司 | Cell pressure volume correction method, device, system and storage medium |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954207A (en) * | 2004-05-14 | 2007-04-25 | 拜尔健康护理有限责任公司 | Methods for performing hematocrit adjustment in glucose assays and devices for same |
| CN101943673A (en) * | 2009-07-07 | 2011-01-12 | 北京怡成生物电子技术有限公司 | Electrochemical biosensor and fabrication method thereof as well as cell packing correction method |
| CN105378465A (en) * | 2013-06-27 | 2016-03-02 | 生命扫描苏格兰有限公司 | Temperature compensation for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte |
| CN107209174A (en) * | 2014-11-25 | 2017-09-26 | 聚合物技术***公司 | System and method by alternating current impedance phase-angle detection to determine electrochemistry hematocrit value |
| CN108680622A (en) * | 2018-05-23 | 2018-10-19 | 北京乐普医疗科技有限责任公司 | Packed cell volume measures and the method for correction in a kind of electrochemica biological sensor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7494816B2 (en) * | 1997-12-22 | 2009-02-24 | Roche Diagnostic Operations, Inc. | System and method for determining a temperature during analyte measurement |
| US20080248581A1 (en) * | 2007-04-06 | 2008-10-09 | Bayer Healthcare Llc | Method for performing correction of blood glucose assay bias using blood hemoglobin concentration |
| AU2012300836B2 (en) * | 2011-09-02 | 2015-02-12 | Lifescan Scotland Limited | Hematocrit corrected glucose measurements using phase angles and impedance for electrochemical test strip |
| US20160091451A1 (en) * | 2014-09-25 | 2016-03-31 | Lifescan Scotland Limited | Accurate analyte measurements for electrochemical test strip to determine analyte measurement time based on measured temperature, physical characteristic and estimated analyte value |
-
2020
- 2020-02-24 CN CN202010110722.8A patent/CN111239227B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1954207A (en) * | 2004-05-14 | 2007-04-25 | 拜尔健康护理有限责任公司 | Methods for performing hematocrit adjustment in glucose assays and devices for same |
| CN101943673A (en) * | 2009-07-07 | 2011-01-12 | 北京怡成生物电子技术有限公司 | Electrochemical biosensor and fabrication method thereof as well as cell packing correction method |
| CN105378465A (en) * | 2013-06-27 | 2016-03-02 | 生命扫描苏格兰有限公司 | Temperature compensation for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte |
| CN107209174A (en) * | 2014-11-25 | 2017-09-26 | 聚合物技术***公司 | System and method by alternating current impedance phase-angle detection to determine electrochemistry hematocrit value |
| CN108680622A (en) * | 2018-05-23 | 2018-10-19 | 北京乐普医疗科技有限责任公司 | Packed cell volume measures and the method for correction in a kind of electrochemica biological sensor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111239227A (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111239227B (en) | Erythrocyte volume correction method and biosensor testing device | |
| EP2193367B1 (en) | Method for correcting erroneous results of measurement in biosensors and apparatus using the same | |
| US6576117B1 (en) | Method and apparatus for electrochemical measurement using statistical technique | |
| US6645368B1 (en) | Meter and method of using the meter for determining the concentration of a component of a fluid | |
| JP3848993B2 (en) | Method and apparatus for measuring the amount of components in the presence of coexisting substances | |
| TWI525322B (en) | Method of measurement of sample to be analyzed | |
| KR20080003421A (en) | Analyte determination method and analyte meter | |
| US20100089774A1 (en) | Non-enzymatic electrochemical method for simultaneous determination of total hemoglobin and glycated hemoglobin | |
| EP3879261A1 (en) | Potentiometric biosensor and detection method | |
| KR101357134B1 (en) | Method for Measuring Analytes in Blood Samples Using Electrochemical Biosensor and a Portable Analyzer | |
| CN111239229B (en) | Dual-channel electrochemical biosensor and method for measuring heme concentration | |
| CN105891297A (en) | Electrochemical measurement method | |
| CN111812175B (en) | Blood detection method for reducing interference of hematocrit and biosensor | |
| CN113049652B (en) | Electrochemical measurement method | |
| CN104535631B (en) | A kind of electrochemical measuring method | |
| US20170038331A1 (en) | System and method for compensating sample-related measurements based on polarization effects of test strips | |
| CN111239228A (en) | Electrochemical biosensor and method for measuring blood impedance phase angle | |
| CN210113571U (en) | Electrode test paper with impedance test function | |
| KR20210042486A (en) | Electrochemical biosensor and manufacturing method thereof | |
| US20180231490A1 (en) | Method for calculating hematocrit in blood, method for calibrating biochemical index value in blood, and system thereof | |
| US20230168240A1 (en) | Systems and methods for hematocrit impedance measurement using 4-wire measurement | |
| CN114544732A (en) | Apparatus and method for measuring glucose | |
| CN115876864A (en) | Test correction method and system for electrochemical sensor | |
| CA2481622C (en) | An apparatus and method for determining the concentration of a component in a fluid | |
| CN108426927A (en) | Hematocrit is than computational methods, biochemical indicator data calibration method and correction system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220110 Address after: 212300 Yunyang Industrial Park, Danyang City, Zhenjiang City, Jiangsu Province Applicant after: JIANGSU YUYUE MEDICAL EQUIPMENT&SUPPLY Co.,Ltd. Applicant after: Jiangsu Yuyue kailite Biotechnology Co.,Ltd. Address before: 212300 Yunyang Industrial Park, Danyang City, Zhenjiang City, Jiangsu Province Applicant before: JIANGSU YUYUE MEDICAL EQUIPMENT&SUPPLY Co.,Ltd. Applicant before: JIANGSU YUYUE INFORMATION TECHNOLOGY SYSTEM Co.,Ltd. Applicant before: SUZHOU YUYUE MEDICAL TECHNOLOGY Co.,Ltd. Applicant before: SUZHOU MEDICAL APPLIANCE FACTORY Applicant before: NANJING YUWELL SOFTWARE TECHNOLOGY Co.,Ltd. Applicant before: TIBET YUYUE MEDICAL INVESTMENT Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |